Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Von Eschenbach’s post-FDA plans

Executive Summary

Former FDA commissioner Andrew von Eschenbach will split his time between MD Anderson and the regulatory consulting firm Greenleaf Health LLC, which he will join as senior advisor. He returns to the University of Texas MD Anderson Cancer Center in Houston as an adjunct professor and will also serve on the advisory board of the David Koch Center for Applied Research in Genitourinary Cancers. On the policy side, von Eschenbach says he will use Greenleaf Health as a "launching pad" to participate in the discussion of macro health issues like personalized medicine, genomics and informatics. In joining Greenleaf, von Eschenbach reunites with his former FDA chief of staff, Patrick Ronan. Ronan founded the consulting firm after leaving the agency in December 2006. Von Eschenbach resigned as FDA commissioner upon the inauguration of President Barack Obama; his successor has not yet been named (1"The Pink Sheet" DAILY, Dec. 16, 2008)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS050769

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel